Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
ANX-007 by Annexon for Geographic Atrophy: Likelihood of Approval
ANX-007 is under clinical development by Annexon and currently in Phase III for Geographic Atrophy. According to GlobalData, Phase III...
Data Insights
Risk adjusted net present value: What is the current valuation of Annexon's ANX-007?
ANX-007 is a monoclonal antibody commercialized by Annexon, with a leading Phase III program in Geographic Atrophy. According to Globaldata,...